SCHEMBL1055833

SCHEMBL1055833

COc1cccc(CC#N)c1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.56
ALOX5 P09917 2/20 0.54
PTGS2 P35354 1/20 0.54
MAPT P10636 5/20 0.52
ALDH1A1 P00352 4/20 0.52
KDM4E B2RXH2 3/20 0.52
HPGD P15428 3/20 0.52
ALOX15 P16050 3/20 0.52
HSD17B10 Q99714 2/20 0.52
CYP3A4 P08684 2/20 0.52
LMNA P02545 1/20 0.52
TP53 P04637 1/20 0.52
ALOX12 P18054 1/20 0.52
MAPK1 P28482 1/20 0.52
CALM1 P0DP23 1/20 0.51
GAA P10253 5/20 0.48
GFER P55789 1/20 0.48
TSHR P16473 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL198463 0.81 IDO1 (0.52) IDO1MAPTALDH1A1LMNAGAA
SCHEMBL12683187 0.80 TSHR (0.40) IDO1ALOX5PTGS2MAPTALDH1A1
SCHEMBL4160051 0.80 SMN1; SMN2 (0.46) ALDH1A1KDM4EHPGDHSD17B10CYP3A4
SCHEMBL506269 0.80 NPC1 (0.40) IDO1MAPTALDH1A1MAPK1CALM1
SCHEMBL31331829 0.79 IMPDH2 (0.47) IDO1MAPTKDM4EALOX15HSD17B10
SCHEMBL31614246 0.79 HTR2A (0.40) IDO1ALDH1A1KDM4ETSHRNPC1
SCHEMBL29893619 0.79 HTR2A (0.42) IDO1MAPTALDH1A1GAATSHR
SCHEMBL3239941 0.79 HTR2A (0.42) IDO1MAPTALDH1A1GAATSHR
SCHEMBL8858519 0.79 IMPDH2 (0.47) IDO1MAPTKDM4EALOX15HSD17B10
SCHEMBL13904952 0.77 TSHR (0.38) IDO1ALOX5PTGS2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872014-B2 Anaplastic lymphoma kinase modulators and methods of use EXELIXIS, INC. (US) 2011-01-18 US disclosed
EP-1648455-A4 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2009-03-04 EP disclosed
US-20070032515-A1 Anaplastic lymphoma kinase modulators and methods of use EXELIXIS, INC. (US) 2007-02-08 US disclosed
EP-1648455-A2 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2006-04-26 EP disclosed
WO-2005009389-A2 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-02-03 WO disclosed
US-4209539-A HYDRATION OF TOXIC CYANO GROUPS TO AMIDE ANVER BIOSCIENCE DESIGN, INC. (US) 1980-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032515-A1 Anaplastic lymphoma kinase modulators and methods of use ALK, MALT1, BCL6 IDO1 2704/4885ALOX5 809/4885PTGS2 1818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.